Search
Acetylcysteine
go.drugbank.com/drugs/DB06151ApprovedInvestigational[A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.[L31488] … [L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.
Mixtures: N-ACETILCISTEÍNA MAS GUAYACOLATO DE GLICERILO, ACETILCISTEINA GUAYACOLATO DE GLICERILO JARABECategories: Compounds used in a research, industrial, or household settingCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationalCefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics. … [FDA Label] This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial
Categories: Compounds used in a research, industrial, or household settingAzilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigational[A232863] Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs. … It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011.
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis. … [L48501] The European Commission also approved the marketing of etrasimod on February 19, 2024.[L50998]
Hydrocodone
go.drugbank.com/drugs/DB00956ApprovedIllicitInvestigationalThe FDA first approved Hydrocodone for use as part of the cough suppressant syrup Hycodan in March of 1943.[L9025] … Hydrocodone is a synthetic opioid derivative of codeine.[T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain.
Mixtures: Novahistex Dh, Vasofrinic DhZanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigationalIn August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia.[L39030] This indication is valid in the US, Europe, and Canada. … L10166] which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexVilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigationalVilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity. … It consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions of heavy and light chain regions) and human gamma 4 heavy chain and light kappa chain constant regions
Triethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigational[A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and … Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine].
Categories: Compounds used in a research, industrial, or household settingGemfibrozil
go.drugbank.com/drugs/DB01241ApprovedInvestigational[L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525] … Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.
Products: GEMFIBROZIL DOC GENERICIBelatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalStructurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. … FDA approved on June 15, 2011.